# OnCo record esr1-mutation-ctdna (biomarker). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/biomarkers/esr1-mutation-ctdna/>
  a schema:MedicalTest ;
  onco:kind "biomarker" ;
  schema:identifier "esr1-mutation-ctdna" ;
  schema:name "ESR1 mutation (ligand-binding domain, usually in ctDNA)"@en ;
  schema:alternateName "ESR1 mutation"@en, "ESR1-mutated"@en, "ESR1 Y537S"@en, "ESR1 D538G"@en, "ESR1m"@en, "ESR1 mutant breast cancer"@en, "acquired ESR1 mutation"@en ;
  schema:description "ESR1 mutations arise in the oestrogen receptor's ligand-binding domain after aromatase inhibitor treatment, letting the receptor work without oestrogen. They are usually found in a blood test and select the oral SERDs elacestrant and imlunestrant."@en ;
  schema:url <https://onco.cc/biomarkers/esr1-mutation-ctdna/> ;
  schema:dateModified "2026-09-23"^^xsd:date ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=aa66ae5c-2bd2-4444-8178-b55651e054ef>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5bc172e4-e8a2-441a-be52-279a7f890196> ;
  onco:tag "biomarker", "hormone-receptor", "resistance" ;
  onco:related <https://onco.cc/biomarkers/er-status/>, <https://onco.cc/biomarkers/pik3ca-hotspot-mutation/> ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/hr-positive-metastatic-post-cdk46/> ;
  onco:drugs <https://onco.cc/drugs/elacestrant/>, <https://onco.cc/drugs/imlunestrant/>, <https://onco.cc/drugs/camizestrant/>, <https://onco.cc/drugs/guardant360-cdx/> ;
  onco:terms <https://onco.cc/terms/esr1-mutation/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/serd/> .